Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Subscribe To Our Newsletter & Stay Updated